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Abstract: Denosumab is a breakthrough biological drug approved by the Food and Drug 
Administration and European Medicines Agency for the treatment of osteoporosis in 2010. 
It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand   antibody, 
which inhibits the activity of osteoclasts, resulting in an antiresorptive effect with a significant 
increase in bone mineral density. The FREEDOM (Fracture Reduction Evaluation of   Denosumab 
in Osteoporosis every 6 Months) trial, comparing denosumab with no treatment in 7868 
women with postmenopausal osteoporosis, showed an important reduction of fracture risk 
at hip,   vertebral, and nonvertebral sites in the treated group, while no statistically significant 
difference in the incidence of adverse events was detected between denosumab and placebo 
groups. The specific action of denosumab directed against a key regulator of osteoclasts makes 
it a valuable tool in preventing the occurrence of skeletal events caused by bone destruction in 
patients with advanced malignancies. The drug was approved for postmenopausal osteoporosis in 
women at increased risk of fracture and for the treatment of bone loss associated with androgen 
d  eprivation therapy in men with prostate cancer.
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Introduction
The aim of osteoporosis treatment is to reduce as far as possible the risk of bone 
fracture. Osteoporosis, the most common metabolic bone disease, is characterized by 
low bone mineral density (BMD) and microarchitectural deterioration of bone tissue 
with a consequent increase in the susceptibility to fragility fractures. It has become 
an increasingly important public health problem due to the rapidly aging population. 
Currently, every third postmenopausal woman and every fifth man older than 50 years 
suffer from osteoporosis.1
It should be important to identify the possible pathological mechanisms underlying 
bone fragility, especially in populations at risk such as the elderly and postmenopausal 
women. Bone strength, ie, resistance to fracture, depends not only on bone mass, 
but also on its spatial distribution and the intrinsic properties of the materials that 
constitute the bone.1,2
Data from the National Osteoporosis Risk Assessment study revealed that only 
6.4% of postmenopausal women with an osteoporotic fracture had T-score (the standard 
deviation difference between the patient’s BMD and the mean BMD of a female young 
adult reference population) of less than −2.5 (World Health Organization definition 
of osteoporosis) in the year preceding the fracture.3,4
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More than one-half (52%) of the women with fractures 
were osteopenic (T-score −2.5 to −1)3,4 and, similarly, the 
increase in BMD achieved through the treatments for osteo-
porosis seemed to account for only part of the reduction of 
fracture risk observed.4,5
Knowledge of the molecular bases of bone metabolism 
would be essential to formulate drugs that act not only on BMD 
but also on bone quality, especially in order to reduce fracture 
risk. Moreover, as described below, prescription of the therapy 
for osteoporosis, which must be specific to the individual 
patient, should be the result of the evaluation of multiple factors, 
such as age, sex, severity of osteoporosis, bone turnover markers 
(bone formation or resorption), patient compliance, allergies to 
medications, and contraindications or side effects of drugs.
Behind the choice of the most appropriate therapy, is the 
concept of bone as a dynamic tissue, which has the ability to 
adapt its shape and size in response to mechanical loads through 
modeling process, and to be constantly renewed by remodeling 
phenomenon.1,6 Remodeling process allows the skeleton to 
maintain mechanical integrity through constant osteoclastic 
resorption of damaged bone followed by osteoblast-mediated 
deposition and mineralization of new matrix.
Antiosteoporosis drugs can be classified on the basis of 
their action on bone remodeling.7 Antiresorptive drugs (such 
as bisphosphonates, raloxifene – a selective estrogen receptor 
modulator, and denosumab) decrease bone remodeling and 
reduce fractures by preserving skeletal microarchitecture and 
moderately increasing bone mass.1 Anabolic drugs, such as 
teriparatide or parathyroid hormone (PTH) 1-84, on the other 
hand, reduce fractures by enhancing remodeling. In addition to 
increasing BMD, they appear to repair bone microarchitecture 
and improve bone geometry.1 Strontium ranelate, available for 
osteoporosis in Europe, decouples the two processes, inhib-
iting bone resorption and stimulating bone formation.1 The 
evidence for this suggested mechanism of action of strontium 
ranelate has been largely acquired from in vitro and animal 
studies, where doses 30 times higher than those appropriate 
for men were used.8 However, bone anabolic effect has not 
been demonstrated in animals treated with doses of strontium 
ranelate comparable to the marketed dose,9 nor in human 
paired bone biopsies by clinical studies.1
A large body of scientific evidence derives from ran-
domized controlled trials concerning the treatment of 
postmenopausal osteoporosis. Three different aminobis-
phosphonates (alendronate, risedronate, and zoledronate), 
teriparatide, strontium ranelate, and hormone replacement 
therapy – which is no longer recommended for the pre-
vention or treatment of osteoporosis – were shown to be 
effective against both vertebral and nonvertebral fractures. 
Evidence of efficacy against vertebral fractures is available 
for ibandronate (an aminobisphosphonate), raloxifene, and 
PTH 1-84.1,10 Table 1 shows the site of action and effect 
on BMD and bone turnover of the most commonly used 
antiosteoporosis drugs.
In women with osteoporosis, each 1% improvement 
in spine BMD (measured by dual X-ray absorptiometry) 
is expected to reduce vertebral fracture risk by about 4%. 
However, randomized trials of antiresorptive agents show 
that 1%–6% improvements in spine BMD reduce vertebral 
fracture risk by 35%–50%. Less than 20% of the decreased 
spine fracture risk produced by alendronate or raloxifene can 
be explained by improvement in spine BMD. The discrepancy 
is even greater during the first year or two of treatment when 
1%–4% improvements in BMD are associated with 65%–68% 
decreases in spine fracture risk. Bisphosphonates continue 
to increase BMD but the reduction in fracture risk wanes 
to 20%–45%. Dual X-ray absorptiometry underestimates 
the change in bone density of spinal trabecular bone, which 
might explain part of the discrepancy between expected and 
observed reductions in spine fracture risk. Even more accurate 
measurements of BMD would not explain the rapid onset and 
later waning of effect despite gradually increasing BMD.11
The effect of drugs on nonspine fracture risk is more 
complex and cannot be predicted from changes in dual X-ray 
Table 1 Osteoporosis therapies in use1
Drug class Drugs Action on bone  
remodeling
Action on bone mineral  
density
Action on vertebral and  
nonvertebral fracture risk
Antiresorptive agents Aminobisphosphonates ↓↓ ↑ v ↓; Nv ↓
Raloxifene ↓ ↑ v ↓
Denosumab ↓↓↓ ↑ v ↓; Nv ↓
Uncoupling agent Strontium ranelate ↓ OC, ↑OB ↑ v ↓; Nv ↓
Anabolic agents PTH 1-84 ↑ ↑↑ v ↓; Nv ↓
Teriparatide ↑ ↑↑ v ↓; Nv ↓
Notes: ↑ increase; ↓ decrease; ↑↑ or ↓↓ strong increase or decrease,  respectively. Adapted from International Journal of Clinical Rheumatology, June 2011, vol. 6, No. 3, Pages 
359–369 with permission of Future Medicine Ltd.
Abbreviations: OB, osteoblast; OC, osteoclast; Nv, nonvertebral; PTH, parathyroid hormone; v, vertebral.
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absorptiometry BMD. Long-term use (.10 years) of estro-
gen, for example, has been associated with .50% reduction 
in risk of hip and wrist fracture, which could not be explained 
by improvements in BMD, and increased section modulus 
versus nonusers with a net increase in predicted femoral neck 
strength despite losing about 0.4% per year in femoral neck 
BMD.12 PTH reduces spine fracture risk and this effect is 
more completely explained by improvement in spine BMD. 
This suggests that sustaining increased BMD produced by 
PTH may maintain long-term reduction in fracture risk.
The choice of the most appropriate therapy for indi-
vidual patients should be based on the level of turnover rate 
indicated by biochemical markers, therefore preferring an 
anticatabolic drug in the case of high bone turnover post-
menopausal woman and an anabolic or decoupling drug in 
an old patient with low turnover indices or a very low spinal 
and/or hip BMD. Importantly, patients’ compliance with 
medical therapy should be considered when choosing drugs 
with a certain frequency of administration.1
Alendronate, risedronate, and ibandronate were marketed 
with administration schedules that increasingly simplified 
oral therapy from once daily to weekly and then to monthly. 
A third-generation bisphosphonate, zoledronate, is provided 
in the form of a brief intravenous infusion administered 
yearly. The therapeutic plan for PTH involves daily subcuta-
neous administration performed at the same time for a maxi-
mum period of 24 consecutive months overall.   Denosumab, 
the latest one on the market, requires a subcutaneous injection 
every 6 months.
Moreover, osteoporosis type (postmenopausal, senile, or 
secondary to pathologies or to the use of drugs), potential 
side effects, allergies, drug-specific contraindications, and 
the cost of treatment should be considered.1
The different drug classes: 
mechanisms of action
Bisphosphonates
Bisphosphonates are antiresorptive agents which act via the 
inhibition of osteoclasts, leading to reduced bone turnover, 
increased bone mass, and improved mineralization.13
Bisphosphonates are chemically stable analogues of inor-
ganic pyrophosphate; publications of their biological effects 
began in 1969.14 Studies on the role of inorganic pyrophos-
phate as the body’s natural “water softener” in the control 
of soft tissue and skeletal mineralization led to the need to 
find inhibitors of calcification that would resist hydrolysis 
by alkaline phosphatase.14 The   observation that inorganic 
pyrophosphate and bisphosphonates could not only retard 
the growth but also the dissolution of hydroxyapatite crystals 
prompted studies on their ability to inhibit bone resorption.14 
Although inorganic pyrophosphate was unable to do this, bis-
phosphonates turned out to be remarkably effective inhibitors 
of bone resorption in both in vitro and in vivo experimental 
systems, and eventually in humans. As more potent bispho-
sphonates were synthesized and studied, it became apparent 
that physicochemical effects were insufficient to explain their 
biological effects and that cellular actions must be involved. 
Despite many attempts, it was not until the 1990s that their 
biochemical actions were elucidated. Selectively taken up and 
adsorbed to mineral surfaces in bone, bisphosphonates are 
internalized by the bone-resorbing osteoclasts and interfere 
with specific biochemical processes.
Bisphosphonates can be classified into at least two groups 
with different molecular modes of action. The simpler 
nonnitrogen-containing bisphosphonates (such as etidronate 
and clodronate) can be metabolically incorporated into non-
hydrolysable analogues of adenosine triphosphate, which 
interfere with adenosine triphosphate-dependent intracellular 
pathways.14 The more potent nitrogen-containing bisphos-
phonates (including pamidronate, alendronate, risedronate, 
ibandronate, and zoledronate) are not metabolized in this 
way but inhibit key enzymes of the mevalonate/cholesterol 
biosynthetic pathway, such as farnesyl pyrophosphate 
  synthase. They therefore interfere with geranylgeranylation 
(attachment of the lipid to regulatory proteins) and with the 
biosynthesis of isoprenoid compounds (notably farnesol 
and geranylgeraniol) that are required for posttranslational 
prenylation of small guanosine triphosphate-binding pro-
teins (which are also guanosine triphosphatases), essential 
intracellular messengers, thus causing osteoclast inactiva-
tion.13,14 Loss of geranylgeranylation leads to osteoclast 
apoptosis,15,16 disruption of the actin cytoskeleton, and altered 
membrane trafficking.13,17–19 This mechanism is responsible 
for nitrogen-containing bisphosphonate suppression of 
osteoclastic bone resorption and reduction of bone turnover, 
which leads to fracture prevention.13
Because of the appearance in humans of gastrointestinal 
adverse events after oral administration of nitrogen-containing 
bisphosphonates,20 the effects of oral bisphosphonates were 
examined in special studies in animals. Suprapharmacologic 
doses of alendronate administered orally to rats have been 
reported to induce gastric and esophageal erosions and 
ulcerations, as well as delay healing of indomethacin-induced 
gastric erosions. These effects were not attributable to changes 
in gastric acid secretion or prostaglandin   synthesis, but are 
thought to be due to a topical irritant effect. Similar effects 
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were reported with etidronate, risedronate, and tiludronate 
when given at pharmacologically equivalent doses.13,21–23
Accumulation of the upstream metabolite, isopentenyl 
pyrophosphate, as a result of inhibition of farnesyl pyrophos-
phate synthase may be responsible for immunomodulatory 
effects on gamma delta T cells, and can also lead to produc-
tion of another adenosine triphosphate metabolite called 
ApppI, which has intracellular actions.14
Bisphosphonates are established as the treatments of 
choice for various diseases of excessive bone resorption, 
including Paget’s disease of bone, skeletal complications of 
malignancy, and primarily osteoporosis.
Recently, it has been suggested that in addition to inhibit-
ing osteoclasts, bisphosphonates (specifically alendronate) 
may also promote osteoblast proliferation and maturation.4,24 
The evidence base for bisphosphonates in the prevention 
of fracture in postmenopausal women is well established.4 
Treatment with alendronate 10 mg/day resulted in statistically 
significant reductions in vertebral, nonvertebral, hip, and 
wrist fractures in patients with prior osteoporotic fracture or 
low BMD. For those patients without osteoporotic fracture or 
low BMD, treatment with alendronate resulted in a significant 
reduction in vertebral, but not other sites, fracture.4,25 Similar is 
the antifracture efficacy of risedronate 5 mg/day, although the 
reduction in wrist fractures in patients with prior fracture or low 
BMD was not statistically significant and there was no signifi-
cant benefit in patients with normal BMD.4,26 Treatment with a 
once-yearly infusion of zoledronate (5 mg) significantly reduces 
the risk of vertebral, nonvertebral, hip, and wrist fracture in 
postmenopausal women with osteoporosis.4,27 In contrast, 
ibandronate in women with postmenopausal osteoporosis has 
shown a significant reduction in vertebral fracture only.4,28
Bisphosphonates improve trabecular microarchitecture; 
however, they have a relatively small effect on cortical bone. 
Trabecular microarchitecture is improved (greater bone vol-
ume, greater trabecular thickness, decreased trabecular spac-
ing) after 2–3 years of alendronate treatment compared with 
placebo,29 or after 1 year of treatment with risedronate.30
In regards to the optimal treatment period, it should 
be considered that both alendronate and zoledronate bind 
strongly to the bone matrix and become internalized within 
bone; therefore, suppression of bone resorption continues 
even after treatment ends. There have been recent concerns 
that long-term suppression of bone remodeling and increased 
mineralization may result in detrimental changes to bone 
quality and accumulation of damage.4,31
Postmenopausal osteoporosis is a chronic disease 
requiring long-term management. While most antiosteoporotic 
treatments have been tested in 3–5-year studies, it should be 
crucial to assess the long-term safety and efficacy of these 
agents.32
Strontium ranelate
Strontium ranelate is a divalent strontium salt comprised 
of two molecules of stable strontium and one molecule of 
ranelic acid (Figure 1).33,34 It is a bone-seeking agent capable 
of increasing bone formation and reducing bone resorption, 
thereby uncoupling and rebalancing bone turnover in favor 
of bone formation.33–35
Strontium ranelate has been shown to increase bone for-
mation in vitro, enhancing preosteoblastic cell replication and 
osteoblastic differentiation and decreasing abilities of osteo-
blasts to induce osteoclastogenesis via the calcium-sensing 
receptor and an increase in the osteoprotegerin (OPG)/
receptor activator of nuclear factor kappa-B (RANK) ligand 
(RANKL) ratio.36 In human primary osteoblasts, strontium 
ranelate downregulated the expression of RANKL (which 
induces the differentiation of mature osteoclasts and increases 
osteoclast survival) and enhanced OPG expression (which 
inhibits RANKL-induced osteoclastogenesis), thus reducing 
osteoclastogenesis.34
Strontium, like calcium, acts as an agonist at the calcium-
sensing receptor, promoting replication,36 differentiation,36,37 
and survival36 of rodent37,38 or human36 primary osteoblasts. 
The drug triggers mitogenic signals, such as the activation of 
protein kinase C and p38 mitogen-activated protein kinase,39 
and enhances the expression of c-Fos and EGR-1 genes, 
involved in osteoblast replication.37 The drug may act inde-
pendently of the calcium-sensing receptor by protecting 
primary osteoblasts against apoptosis, thereby promoting 
osteoblastogenesis – partly via extracellular signal-related 
kinases 1/2 and Akt signaling – and prostaglandin E2 
production.34,40
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Figure 1 Strontium ranelate structure.
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In rats,8 2 years’ treatment with strontium ranelate 
increased bone resistance (assessed by a compression test) 
and trabecular and cortical bone mass (as shown by ash 
weight and areal BMD in the vertebra and femur), with an 
improvement in bone microarchitecure.8,34 Similar effects 
were observed in women with postmenopausal osteoporosis 
in whom oral administration of strontium ranelate 2 g/day led 
to continued increases in BMD at all sites, proving efficacy 
against vertebral and nonvertebral fracture over 5 years, as 
demonstrated in the SOTI (Spinal Osteoporosis   Therapeutic 
Intervention) trial41 and in the TROPOS (  Treatment of Periph-
eral Osteoporosis) trial,42,43 though many women required 
longer-term treatment.32 No studies have been   performed on 
strontium ranelate efficacy on men.
PTH
Until the advent of teriparatide (human recombinant PTH 
1-34), the only available therapies for the treatment of 
osteoporosis worked by primarily inhibiting bone resorp-
tion (  bisphosphonates, raloxifene, and estrogen), which 
decrease the rate of bone turnover by reducing the level of 
bone resorption with a subsequent reduction of bone forma-
tion activity.44,45
There is evidence from randomized controlled trials on 
the efficacy of antiresorptives in reducing the risk of fracture, 
but none of these agents completely abolish fracture risk. 
Although they reduce fracture risk, particularly in the spine, 
there is no increase in bone formation or restoration of archi-
tectural bone tissue damage after treatment.46 Enhancement 
of bone formation may be provided by anabolic therapies.
PTH, the major hormonal regulator of calcium homeostasis, 
is a potent stimulator of bone formation and can restore bone 
to an osteopenic skeleton when administered   intermittently.1 
Osteoblasts are the primary target cells for the anabolic effects of 
PTH in bone tissue. Anabolic effects of PTH on bone have been 
demonstrated in animals and humans by numerous measure-
ment techniques including BMD and bone   histomorphometry. 
Recently, two-dimensional and   three-dimensional assessments 
of cancellous bone structure have shown that PTH can rees-
tablish lost trabecular connectivity in animals and humans by 
a novel mechanism in which trabeculae are first thickened and 
then split by longitudinal tunneling.47
These results provide new insight into the positive clinical 
effects of PTH in osteoporosis. In recent randomized con-
trolled clinical trials of intermittent PTH treatment, PTH 
decreased incidence of vertebral and nonvertebral fractures 
in postmenopausal women. Thus, PTH shows strong potential 
as therapy for osteoporosis. However, two-dimensional and 
three-dimensional structural analysis of advanced osteopenia 
in animals has shown that there is a critical limit of trabecular 
connectivity and bone strength below which PTH cannot 
completely reverse the condition. Given that PTH treatment 
fails to completely restore trabecular connectivity and bone 
strength in animals with advanced osteopenia, early treat-
ment of osteoporosis appears important and efficacious 
for preventing fractures caused by decreased trabecular 
connectivity.48
The beneficial effect of introducing a treatment with anti-
resorptives after a treatment course with teriparatide or PTH 
has been demonstrated and is supported by a good rationale. 
Teriparatide increases bone mass but, at the same time, the 
new bone is less mineralized. Treatment with antiresorptives 
after teriparatide prevents accelerated osteoclastic resorp-
tion of the new bone tissue built during teriparatide therapy, 
increases mineralization, and rapidly lowers cortical porosity; 
this leads to further increases in BMD. The cost of teriparatide 
treatment is considerably higher than that of antiresorptives. 
For this reason, its use is indicated for patients with severe 
osteoporosis; in Italy, for example, teriparatide is fully 
reimbursed in patients with a new vertebral or hip fracture 
while on chronic treatment with antiresorptives or in patients 
never treated with antiresorptives with three or more vertebral 
or hip fractures.1,49 Contrary to bisphosphonates, the effect of 
which persists for many months after drug withdrawal,50 the 
protective action of teriparatide on BMD vanishes with time 
in both genders but not up to the baseline values.51,52
Bazedoxifene
Bazedoxifene is a novel third-generation selective estro-
gen receptor modulator, a molecule developed to act as 
estrogen receptor agonists in some tissues (eg, bone) and 
as estrogen receptor antagonists in others, such as breast 
and endometrium, in order to reduce the risk of breast and 
endometrial cancers that would be induced by hormone 
replacement therapy.53,54
Two large Phase III clinical trials54,55 showed that bazedox-
ifene, as well as raloxifene, increased BMD, decreased levels 
of bone turnover markers, and significantly reduced the risk of 
new vertebral fractures in postmenopausal women compared 
with placebo. Although the incidence of nonvertebral fractures 
with bazedoxifene or raloxifene did not differ significantly 
from that with placebo, a post hoc analysis of a subgroup 
of women at higher fracture risk revealed that bazedoxifene 
significantly reduced the nonvertebral fracture risk relative 
to placebo and raloxifene. Bazedoxifene also improved the 
lipid profile by reducing the serum concentrations of total 
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cholesterol and low-density lipoprotein cholesterol, with an 
increase in the serum level of high-density lipoprotein cho-
lesterol. The incidences of vasodilatation (hot flushes), leg 
cramps, and venous thromboembolic events were significantly 
higher with bazedoxifene and raloxifene compared with pla-
cebo. There was no evidence of endometrial and breast stimu-
lation with bazedoxifene. Taking advantage of the favorable 
effects of bazedoxifene on the breast and endometrium, the 
pairing of bazedoxifene with conjugated estrogens is under 
investigation for the treatment of menopausal symptoms 
and prevention of postmenopausal osteoporosis. A Phase 
III trial showed that combination therapy of bazedoxifene 
and conjugated estrogens significantly increased BMD and 
decreased bone turnover markers, with relief of hot flushes 
and improvement of vaginal atrophy.54
Although bazedoxifene is a promising new therapy 
for patients with osteoporosis, further clinical investiga-
tions of long-term treatment with this selective estrogen 
receptor modulator are needed to evaluate the preven-
tion of osteoporotic fractures, breast cancers, endome-
trial cancers, and cardiovascular events. When treating 
patients with osteoporosis, estrogens and selective estro-
gen receptor modulators have effects not only on bone 
metabolism, but also on the breast, endometrium, and 
lipid metabolism. Before starting treatment, a risk–benefit 
assessment should be performed for each patient with   
osteoporosis.54
Denosumab
Background
The principal regulator of bone resorption is the RANKL/
RANK/OPG pathway. RANKL is a transmembrane and 
soluble protein that is highly expressed by osteoblasts;56,57 
its receptor, RANK, is located on the cell membrane of 
osteoclasts and preosteoclasts.57,58 RANKL–RANK binding 
stimulates the formation, activity, and survival of osteoclasts, 
resulting in increased bone resorption.59
OPG is a naturally occurring, soluble, nonsignaling 
“decoy receptor” for RANKL. By binding to RANKL 
and preventing its interaction with RANK, OPG inhibits 
osteoclast formation,59,60 activity,61,62 and survival,63 thereby 
reducing bone resorption.57,60
An increase of RANKL in proportion to OPG is asso-
ciated with the development of postmenopausal osteopo-
rosis and other skeletal disorders that include multiple 
myeloma, metastatic bone disease, treatment-related 
bone loss,   rheumatoid arthritis, and Paget’s disease of 
bone.57,59,64,65
Development of RANKL inhibitors
The understanding of this pathway dates back to the end of the 
1990s, Amgen (Amgen Inc, Thousand Oaks, CA)   researchers 
identified in rats a gene sequence able to influence bone 
metabolism.60,66 Transgenic mice in which they induced the 
hepatic expression of the protein derived from that sequence 
resulted in a profound yet nonlethal osteopetrosis, coincident 
with a decrease in later stages of osteoclast differentiation.60 
These same effects were observed upon administration of 
recombinant OPG into normal mice. Recombinant OPG was 
shown to block osteoclast differentiation from precursor cells 
in vitro.60 In vivo, it stopped ovariectomy-associated bone loss 
in rats. In vivo and in vitro data showed that OPG could act 
as a soluble factor in the regulation of bone mass and be of 
use in the treatment of osteoporosis associated with increased 
osteoclast activity.60
The Amgen research group identified a protein, which 
they called “OPG ligand.”67 The Snow Brand (Snow Brand 
Milk Products Co, Ltd, Tokyo, Japan) researchers isolated 
the same OPG-binding protein, and by comparing gene 
sequences discovered that it was identical to a previously 
described protein named RANKL or tumor necrosis factor-
related activation-induced cytokine.68 Subsequently the 
laboratories of Amgen analyzed osteoclast precursor cells 
and isolated RANK protein, which was discovered to be 
RANKL receptor.69
While transgenic mice knockout for RANK or RANKL 
developed severe osteopetrosis, the overexpression of 
RANKL caused an increase in osteoclasts and a reduction 
in bone strength, and thus caused osteoporosis.70
Several studies showed that pathological loss of bone 
mass, a typical example of postmenopausal osteoporosis, is 
associated with increased RANKL levels and the   consequent 
hyperactivation of osteoclasts.63 Moreover, RANKL levels 
in postmenopausal women are directly proportional to bone 
turnover markers, such as serum C-telopeptide of   collagen 
type 1 and urinary N-telopeptide of collagen type 1 (NTX) – 
degradation products of collagen type 1 released into circula-
tion during resorption of bone matrix.71 Estrogen deficiency is 
also associated with an increment of osteoclasts and RANKL 
levels.71 This evidence led to the development of targeted 
molecules specifically interacting with RANK/RANKL/
OPG pathway.
The entry of denosumab
Denosumab is a fully human monoclonal antibody of the 
immunoglobulin G2 isotype with a high affinity and specific-
ity for RANKL. By binding RANKL, denosumab prevents 
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its interaction with RANK, in much the same way as OPG, 
resulting in a decrease in bone resorption.
Pharmacokinetics of denosumab
The pharmacokinetics of denosumab are nonlinear with 
dose, similar to other fully human monoclonal antibodies. 
In healthy postmenopausal women given subcutaneous 
denosumab in varying doses, three phases were identified: 
(1) a prolonged absorption phase with maximum serum 
concentration observed at 5–21 days postdose, increasing 
as dose increased; (2) a prolonged phase, with serum half-
life as long as 32 days with maximum dose; and (3) a rapid 
terminal phase when serum concentration dropped below 
1000 ng/mL.72
Efficacy and safety studies
The effect on bone remodeling of denosumab was assessed 
in a Phase I study72 by measurement of bone turnover 
markers, such as NTX, marker of bone resorption, and 
bone-specific alkaline phosphatase, a marker of bone for-
mation. Forty-nine healthy postmenopausal women were 
treated with a single dose of subcutaneous denosumab 0.01, 
0.03, 0.1, 0.3, 1.0, or 3.0 mg/kg or placebo, and followed 
for up to 6 months in all cohorts and as long as 9 months 
in the cohorts receiving the three highest doses.57,72 A 
reduction in NTX levels was observed that was dose-
dependent, rapid (within 12 hours), profound (up to 84% 
decrease), sustained (for up to 6 months), and reversible 
with discontinuation. Reduction of bone-specific alkaline 
phosphatase was observed later than with NTX and was 
less pronounced.
The efficacy and safety of denosumab were evaluated 
in a Phase II randomized placebo-controlled study in post-
menopausal women with low BMD, defined as lumbar spine 
T-score of −1.8 to −4.0 or total hip or femoral neck T-score of 
−1.8 to −3.5.57,73–74 A total of 412 women were randomized 
to receive subcutaneous denosumab 6, 14, or 30 mg every 
3 months or 14, 60, 100, or 210 mg every 6 months, open-
label oral alendronate 70 mg once a week, or placebo. The 
primary endpoint was the percentage change in lumbar spine 
BMD at 12 months compared to baseline. Other endpoints 
included the percentage change from baseline in BMD at the 
total hip, femoral neck, distal one-third radius, and assess-
ment of bone turnover with serum C-telopeptide of collagen 
type 1, urinary NTX, and bone-specific alkaline phosphatase. 
At 12 months, denosumab treatment was associated with 
a significant lumbar spine BMD increase of 3.0%–6.7%, 
depending on the dose and dosing interval, with smaller 
significant BMD increases observed at other skeletal sites.73 
BMD increases at the total hip and distal one-third radius 
with subcutaneous denosumab 30 mg every 3 months and 
60 mg every 6 months were greater than with open-label 
alendronate.
Treatment with denosumab resulted in a dose-dependent, 
rapid, sustained, and reversible suppression of bone turnover 
markers.57 The data at 24 months supported and extended the 
findings at 12 months, with continuing increases in BMD and 
suppression of bone turnover markers.74
The study was extended for 24 months beyond the initial 
24 months.75 Patients originally randomized to denosumab 
were treated with subcutaneous denosumab 60 mg every 
6 months, placebo, or placebo for 12 months followed by 
retreatment with subcutaneous denosumab 60 mg every 
6 months for 12 months. Open-label alendronate patients 
discontinued alendronate therapy after 24 months and 
received no additional drug therapy. The original placebo 
group was maintained for the entire 48 months. Continuous 
denosumab treatment for 48 months increased BMD at the 
lumbar spine (9.4%–11.8% compared with baseline) and total 
hip (4.0%–6.1% compared with baseline), with consistent 
suppression of bone turnover markers for the duration of 
the study. Discontinuation of denosumab after 24 months 
of treatment was associated with a BMD decrease of 6.6% 
at lumbar spine and 5.3% at total hip within 12 months of 
discontinuation.57
Retreatment with denosumab 12 months after discon-
tinuation increased BMD to an extent similar to what was 
observed with initial treatment (BMD at lumbar spine 
increased 9.0% and at total hip increased by 3.9% compared 
with original baseline values).
Bone turnover marker levels increased with discon-
tinuation of denosumab and decreased with retreatment. 
Discontinuation of alendronate at 24 months resulted in a 
modest decrease in BMD at lumbar spine by 48 months, 
with a greater decrease in BMD at total hip and distal 
one-third radius; bone turnover marker levels increased, 
but remained below baseline at 48 months. The initial 
4-year study was extended an additional 4 years to evaluate 
the efficacy and safety of denosumab with up to 8 years 
of continuous exposure. A preliminary interim analysis 
after 2 years of the extension study (total of 6 years of 
denosumab therapy), with all patients switched to open-
label denosumab at a dose of 60 mg subcutaneously every 
6 months, showed that BMD at lumbar spine increased 
13.3% compared with baseline, with sustained reductions 
in serum C-telopeptide of collagen type 1 and bone-specific 
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alkaline phosphatase.75 No patient developed neutralizing 
antibodies to denosumab.57
FREEDOM (Fracture Reduction Evaluation of Deno-
sumab in Osteoporosis every 6 Months) was a large 3-year 
Phase III clinical trial in 7868 postmenopausal women 
with osteoporosis who were randomized to receive either 
subcutaneous denosumab 60 mg (n = 3902) or placebo 
(n = 3906) every 6 months.76 The primary efficacy endpoint 
was new vertebral fractures at 36 months, with secondary 
endpoints that included time to first hip and nonvertebral 
fractures. Study subjects, between the ages of 60 and 90 
years, had a baseline T-score at lumbar spine or total hip 
between −2.5 and −4.0, with approximately 23% having at 
least one prevalent vertebral fracture at time of entry into 
the study. Treatment with denosumab was associated with 
a statistically significant 68% reduction in the risk of new 
vertebral fractures compared with placebo (2.3% deno-
sumab versus 7.2% placebo, P , 0.0001), 40% reduction 
in the risk of hip fractures (0.7% denosumab versus 1.2% 
placebo, P = 0.036), and 20% reduction in the risk of non-
vertebral fractures (6.5% denosumab versus 8.0% placebo, 
P = 0.011).57,76 There was no increase in the risk of cancer, 
infection, cardiovascular disease, delayed fracture healing, 
or hypocalcemia, and there were no cases of osteonecrosis 
of the jaw and no adverse reactions to the injection of 
denosumab.
DEFEND (Denosumab Fortifies Bone Density) was 
a Phase III trial evaluating the efficacy and safety of 
denosumab in 332 postmenopausal women with low bone 
mass (osteopenia). Postmenopausal women with lumbar 
spine T-scores between −1.0 and −2.5 were randomized to 
receive subcutaneous denosumab 60 mg every 6 months 
or   placebo.77 The primary efficacy endpoint was percent-
age change from baseline in lumbar spine BMD measured 
by dual X-ray absorptiometry at 24 months compared 
to   placebo. Denosumab significantly increased BMD 
at lumbar spine compared with placebo at 24 months 
(denosumab 6.5% versus placebo −0.6%, P , 0.0001), 
as well as at total hip, distal one-third radius, and total 
body (P , 0.0001 for each compared with placebo), 
with a significant decrease in bone turnover markers 
compared with placebo. The safety profile was similar 
to placebo, except for a slightly higher incidence of cel-
lulitis and exanthema. Eczema was reported in 3.0% of 
denosumab-treated patients compared with 1.7% in the 
placebo group (P , 0.001); cellulitis as a serious adverse 
event was more common with denosumab (0.3%) than 
placebo (,0.1%).
DECIDE (Determining Efficacy: Comparison of Initiat-
ing Denosumab Versus Alendronate) was a 1-year Phase III 
double-blind, double-dummy noninferiority trial in 1189 
postmenopausal women with lumbar spine or total hip T-score 
of −2.0 or less who were randomized to receive subcutaneous 
denosumab 60 mg every 6 months plus weekly oral placebo 
or oral alendronate 70 mg weekly plus placebo subcutane-
ous injections every 6 months.78 The primary endpoint 
was percentage change from baseline of total hip BMD at 
12 months in subjects treated with denosumab compared with 
alendronate. At 12 months, there was a significantly greater 
BMD increase with denosumab compared with alendronate 
at total hip (denosumab 3.5% versus alendronate 2.6%, 
P , 0.0001) and all other measured skeletal sites, with treat-
ment difference 0.6% at femoral neck, 1.0% at trochanter, 
1.1% at lumbar spine, and 0.6% at distal one-third radius 
(P , 0.0002 for all sites). There was a statistically significant 
greater reduction in bone turnover markers with denosumab 
compared with alendronate.
STAND (Study of Transitioning from Alendronate to 
Denosumab) was a 1-year Phase III double-blind, active-
controlled, double-dummy study in 504 postmenopausal 
women being treated with alendronate, with lumbar spine 
or total hip T-score between −2.0 and −4.0.79 Subjects were 
randomized to receive subcutaneous denosumab 60 mg every 
6 months or continuing oral alendronate 70 mg weekly. The 
primary endpoint was percentage change in BMD at total 
hip at 12 months for denosumab compared to alendronate. 
At 12 months, there was a statistically significant greater 
increase in BMD with denosumab compared with continu-
ing alendronate at total hip (denosumab 1.90%, alendronate 
1.05%, P , 0.0001), lumbar spine, and distal one-third 
radius. Discontinuing denosumab (at a dose of 210 mg) 
after 24 months resulted in a decrease in BMD in the follow-
ing year comparable to the gains in BMD with 24 months 
of therapy.75 Denosumab has a declining residual effect over 
1 year, a period called offset time.80
Table 2 provides a summary of the principal randomized 
controlled trials conducted with denosumab.
Clinical applications of denosumab
Denosumab has been approved for treatment of postmeno-
pausal osteoporosis, as the data of clinical trials showed 
antifracture efficacy of denosumab to be at least as good as 
current therapeutic agents in the treatment of   postmenopausal 
osteoporosis and is associated with excellent   tolerability. 
It may be particularly important for patients with gastro-
intestinal contraindications or side effects with oral bis-
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phosphonates and for patients with malabsorption.57 The 
long dosing interval of 6 months is likely to be attractive 
to patients who have difficulty with the more frequent and 
sometimes   bothersome requirements for oral bisphosphonate 
therapy. The subcutaneous route of administration expands 
the potential locations for drug administration to any physi-
cian’s office, as compared with intravenous bisphosphonates, 
which are typically given at an infusion center or office with 
staff trained in infusion therapy.57
The clinical significance of the observation of statistically 
significant differences in some individual adverse events 
(eg, sore throat, rash) and serious adverse events (eg, cel-
lulitis, infections requiring hospitalization) is unclear, but 
has raised concern regarding possible adverse effects on the 
immune system. RANKL inhibition might increase the risk 
of infection or malignancy, since RANKL, RANK, and/or 
OPG are expressed in activated T and B lymphocytes, den-
dritic cells, and CD4/CD8 thymocytes,81,82 and RANKL and 
RANK knockout mice have a deficiency of splenic B cells 
and fail to develop lymph nodes.83,84 However, inhibition of 
RANKL in adult humans has not been shown to adversely 
affect measured parameters of immune function.57
No evidence of adverse clinical consequences due to 
bone turnover suppression, eg, increased fracture risk or 
impaired fracture healing, were observed with denosumab.57 
Iliac crest bone biopsy data has shown normal bone quality 
with significant decreases in bone turnover parameters in 
denosumab-treated patients,85,86 consistent with the observed 
effects on bone turnover markers. All placebo-treated patients 
were found to have double label, while 36% of patients treated 
with denosumab had no detectable tetracycline label and 25% 
had only a single label.
The clinical significance of the absence of tetracycline 
label in denosumab-treated patients is uncertain. While 
denosumab appears to be an excellent option as the   primary 
treatment of postmenopausal osteoporosis, it is most 
likely to be used in patients with a contraindication to oral 
  bisphosphonates, gastrointestinal intolerance, malabsorption, 
or poor response to therapy.57
A validated Markov microsimulation model was used 
to estimate the cost (€2009) per quality-adjusted life year 
gained of a 3-year denosumab treatment compared with no 
treatment.80 The model was populated with cost and epide-
miological data for Belgium from a health-care perspective 
and the base–case population was defined from the FREE-
DOM trial.80 This study suggests, on the basis of currently 
available data, that denosumab is cost-effective compared 
with no treatment for postmenopausal Belgian women with 
low bone mass and who are similar to patients included in 
the FREEDOM trial. In addition, denosumab was found to be 
cost-effective at the commonly accepted threshold of €30,000 
per quality-adjusted life year gained in a population currently 
reimbursed in Europe with T-score −2.5 or less or prevalent 
vertebral fracture, aged 60 years and above.80
As well as in postmenopausal osteoporosis, denosumab 
has been examined in rheumatoid arthritis, multiple myeloma, 
breast cancer, prostate cancer, and other solid tumors.87
Androgen deprivation therapy is the cornerstone treat-
ment for metastatic prostate cancer. The profound hypogo-
nadal state is associated with metabolic changes including 
decreased BMD and an increased risk of fracture.87
In postmenopausal women, a single administration of 
denosumab resulted in rapid (within 12 hours), marked 
(80%), and sustained (6 months) suppression of osteoclast 
activity.71 In patients with multiple myeloma or bone metas-
tasis from breast or prostate cancer, denosumab was well 
tolerated and achieved rapid and sustained suppression of 
osteoclast activity,88,89 and has proven efficacy in fracture 
prevention in men on initial androgen deprivation therapy.
Denosumab was superior to zoledronate in treatment of 
bone metastatic disease in castration resistant prostate can-
cer, the one setting in which a bisphosphonate is approved 
for prostate cancer.87 Ongoing Phase III studies will address 
other important unmet medical needs including metastasis 
prevention.87
In patients receiving methotrexate for erosive rheumatoid 
arthritis, denosumab provided protection against erosion, 
not only preventing bone loss but increasing hand BMD as 
measured by dual X-ray absorptiometry.90
Safety information on denosumab
Data is summarized in Table 3 and available in the leaflet 
information of denosumab.
Denosumab and osteonecrosis of the jaw (ONJ)
The FREEDOM trial reported no cases of ONJ in either 
denosumab or placebo group.76 As ONJ and atypical 
femoral subtrochanteric fracture associated with long-term 
  bisphosphonate use are rare, there might be an advan-
tage (albeit small, given the rarity of these events) to the 
use of denosumab. Moreover, since bisphosphonates are 
cleared by the kidney and contraindicated in patients with 
renal   insufficiency, denosumab (which is cleared by non-
renal   metabolism) may prove to be a safe drug in these 
patients, although studies that directly address this issue 
need to be done.91
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All denosumab randomized controlled trials published 
to date include a dosing interval longer than 3 months and a 
cumulative dose of not more than 210 mg per 6 months.92,93 
None of these studies report any cases of ONJ. On the con-
trary, preliminary results of two randomized controlled trials 
studying denosumab for the treatment of bone metastases in 
cancer patients include a monthly dosing interval and a dose 
of 120 mg per month.94,95 Denosumab-related ONJ could be 
a dose-related adverse effect.93
ONJ has been reported to be a much more common event 
in patients receiving bisphosphonates for the treatment and 
prevention of cancer-related skeletal events (mainly intrave-
nously) rather than in those patients receiving bisphospho-
nates (mainly orally) for nonmalignancy indications.96,97
Similar to bisphosphonate-related ONJ pharmacosurveil-
lance and reporting history,98 broad introduction of denosumab 
into clinical practice would allow for the recognition of 
denosumab-related ONJ adverse effect. Common plausible 
mechanisms for the etiopathogenesis of both denosumab- and 
bisphosphonate-related ONJ would encompass defective osteo-
clast differentiation, function, survival, and “fatigue.”99 When 
compared to bisphosphonates, denosumab exhibits the advan-
tage of short clearance time. Thus, more feasible treatment and 
earlier healing of denosumab-related ONJ when compared to 
bisphosphonate-related ONJ could be anticipated.93
Denosumab and atypical fractures
Research from the first 3 years of an open-label extension 
of the pivotal Phase III FREEDOM trial, presented at the 
  American College of Rheumatology 2011 Annual   Meeting, 
showed that long-term use of the antiresorptive agent 
denosumab in postmenopausal women with osteoporosis 
  continues to increase bone density and reduce markers of 
bone turnover, with no increased risk for the atypical fractures 
seen with long-term use of bisphosphonates.100
Further clinical investigations of long-term treatment with 
denosumab are needed to evaluate the possible occurrence 
of atypical fractures.
Conclusion
Denosumab is a promising emerging drug for the   prevention 
and treatment of postmenopausal osteoporosis. Human 
monoclonal antibody to RANK, denosumab 60 mg given 
subcutaneously every six months has shown to increase 
BMD and reduce bone turnover and fracture risk in all the 
fragile sites. It is simple to administer and well tolerated, 
with a safety profile generally similar to placebo, except for 
a slightly higher incidence of cellulitis and exanthema.
T
a
b
l
e
 
2
 
P
h
a
s
e
 
I
I
I
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
o
f
 
d
e
n
o
s
u
m
a
b
 
f
o
r
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
p
o
s
t
m
e
n
o
p
a
u
s
a
l
 
o
s
t
e
o
p
o
r
o
s
i
s
 
o
r
 
o
s
t
e
o
p
e
n
i
a
5
8
S
t
u
d
y
A
i
m
C
o
n
t
r
o
l
 
 
g
r
o
u
p
M
e
a
n
 
a
g
e
 
a
t
 
 
b
a
s
e
l
i
n
e
 
(
y
e
a
r
s
)
M
e
a
n
 
l
u
m
b
a
r
 
s
p
i
n
e
 
 
T
-
s
c
o
r
e
 
a
t
 
b
a
s
e
l
i
n
e
P
r
i
m
a
r
y
 
 
e
n
d
p
o
i
n
t
S
a
m
p
l
e
 
s
i
z
e
 
(
s
u
b
j
e
c
t
s
)
S
t
u
d
y
 
p
e
r
i
o
d
 
(
y
e
a
r
s
)
E
f
fi
c
a
c
y
S
a
f
e
t
y
:
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
 
a
n
d
 
s
e
r
i
o
u
s
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
F
R
E
E
D
O
M
T
r
e
a
t
m
e
n
t
 
 
o
f
 
P
M
O
P
l
a
c
e
b
o
7
2
.
3
−
2
.
8
N
e
w
 
v
e
r
t
e
b
r
a
l
 
 
f
r
a
c
t
u
r
e
s
 
a
t
 
 
3
6
 
m
o
n
t
h
s
7
8
6
8
3
↓
 
v
e
r
t
e
b
r
a
l
 
 
f
r
a
c
t
u
r
e
 
r
i
s
k
.
c
e
l
l
u
l
i
t
i
s
 
a
n
d
 
e
c
z
e
m
a
D
E
F
E
N
D
P
r
e
v
e
n
t
i
o
n
 
 
o
f
 
P
M
O
P
l
a
c
e
b
o
5
9
.
4
−
1
.
6
L
u
m
b
a
r
 
s
p
i
n
e
 
 
B
M
D
 
a
t
 
2
4
 
m
o
n
t
h
s
3
3
2
2
↑
 
B
M
D
.
i
n
f
e
c
t
i
o
n
s
D
E
C
I
D
E
C
o
m
p
a
r
i
s
o
n
 
 
o
f
 
d
e
n
o
s
u
m
a
b
 
 
a
n
d
 
a
l
e
n
d
r
o
n
a
t
e
A
l
e
n
d
r
o
n
a
t
e
6
4
.
4
−
2
.
6
T
o
t
a
l
 
h
i
p
 
B
M
D
 
 
a
t
 
1
2
 
m
o
n
t
h
s
1
1
8
9
1
.
 
↑
 
B
M
D
–
S
T
A
N
D
S
w
i
t
c
h
 
f
r
o
m
 
 
a
l
e
n
d
r
o
n
a
t
e
 
 
t
o
 
d
e
n
o
s
u
m
a
b
C
o
n
t
i
n
u
i
n
g
 
 
a
l
e
n
d
r
o
n
a
t
e
6
7
.
6
−
2
.
6
T
o
t
a
l
 
h
i
p
 
B
M
D
 
 
a
t
 
1
2
 
m
o
n
t
h
s
5
0
4
1
↑
 
B
M
D
 
w
i
t
h
 
 
s
w
i
t
c
h
 
t
o
 
 
d
e
n
o
s
u
m
a
b
–
N
o
t
e
:
 
>
:
 
m
o
r
e
 
i
n
 
t
h
e
 
d
e
n
o
s
u
m
a
b
 
g
r
o
u
p
 
t
h
a
n
 
i
n
 
t
h
e
 
o
t
h
e
r
 
g
r
o
u
p
.
 
D
a
t
a
 
f
r
o
m
 
H
s
u
 
H
,
 
L
a
c
e
y
 
D
L
,
 
D
u
n
s
t
a
n
 
C
R
,
 
e
t
 
a
l
.
 
T
u
m
o
r
 
n
e
c
r
o
s
i
s
 
f
a
c
t
o
r
 
r
e
c
e
p
t
o
r
 
f
a
m
i
l
y
 
m
e
m
b
e
r
 
R
A
N
K
 
m
e
d
i
a
t
e
s
 
o
s
t
e
o
c
l
a
s
t
 
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
 
a
n
d
 
a
c
t
i
v
a
t
i
o
n
 
i
n
d
u
c
e
d
 
b
y
 
o
s
t
e
o
p
r
o
t
e
g
e
r
i
n
 
l
i
g
a
n
d
.
 
P
r
o
c
 
N
a
t
l
 
A
c
a
d
 
S
c
i
 
U
 
S
 
A
.
 
1
9
9
9
;
9
6
(
7
)
:
3
5
4
0
–
3
5
4
5
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
B
M
D
,
 
b
o
n
e
 
m
i
n
e
r
a
l
 
d
e
n
s
i
t
y
;
 
P
M
O
,
 
p
o
s
t
m
e
n
o
p
a
u
s
a
l
 
o
s
t
e
o
p
o
r
o
s
i
s
.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
262
Cavalli and BrandiTherapeutics and Clinical Risk Management 2012:8
Approved by the Food and Drug Administration and 
European Medicines Agency for the treatment of postmeno-
pausal osteoporosis in women at high risk of fracture and for 
the bone loss associated with androgen deprivation therapy 
in men with prostate cancer, denosumab may be particularly 
useful in clinical practice for the treatment of patients who 
have failed or are intolerant to other available osteoporosis 
therapy, eg, patients with gastrointestinal contraindications, 
side effects with oral bisphosphonates, or malabsorption.
Denosumab has also shown promising skeletal effects in 
the treatment of cancer and rheumatoid arthritis.
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